SUBSCRIBE
SUBSCRIBE

Abcuro, Inc.

NEWS
A human hand showing dollar golden coins in the jar with a colored background. Collage Art of finance
Funding
Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion body myositis through clinical trials. Now, Abcuro is eyeing a regulatory submission and potential launch.
February 12, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
IN THE PRESS
Drug Development
Abcuro Initiates Registrational Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis
April 3, 2023
 · 
3 min read
Drug Development
Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia
October 4, 2022
 · 
2 min read
Genetown
Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells
November 5, 2021
 · 
5 min read
Business
Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors
October 19, 2021
 · 
3 min read
Genetown
Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress
October 6, 2021
 · 
2 min read
Genetown
Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis
June 30, 2021
 · 
4 min read
Business
Abcuro Raises $42 Million in Series A-1 Financing, Appoints John B. Edwards as Executive Chair of the Board of Directors and David de Graaf, Ph.D. as Chief Executive Officer
January 7, 2021
 · 
4 min read
Business
ProBioGen and Abcuro Signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement
May 23, 2019
 · 
3 min read
Drug Development
Abcuro Announces Pre-Clinical Data on New Immuno-Oncology Target
March 26, 2019
 · 
1 min read
Load More
JOBS